endo international plc (ENDP) Key Developments
Endo International plc Provides Earnings Guidance for the Twelve Months Ending December 31, 2015 and for the Full Year 2016
Sep 28 15
Endo International plc provided earnings guidance for the full twelve months ending December 31, 2015. Total revenue to be between $3.22 billion and $3.27 billion; and adjusted diluted EPS from continuing operations to be between $4.50 and $4.60 compared to $4.40 and $4.60 estimated in previous guidance. Adjusted effective tax rate of between 9% and 10%; and Adjusted diluted earnings per share from continuing operations assume full year diluted shares outstanding of approximately $201 million.
For full year 2016, the company estimates adjusted diluted EPS from continuing operations to be between $5.85 and $6.15.
Endo International plc Provides Earning Guidance for the Third Quarter of 2015
Sep 28 15
Endo International plc provided earning guidance for the third quarter of 2015. The company expects third quarter 2015 revenues to be between $720 million and $740 million. On an adjusted basis, the company expects third quarter 2015 gross margin and operating expenses to be within previous full year guidance ranges as a percentage of revenues. The company do not expect the net operating results for third quarter from Par to be material. However, the timing of Par-related financing activities will have a material impact on results below the operating line. The company expects adjusted interest expense in the third quarter 2015 to be approximately $95 million. The closing of the Par transaction in the third quarter creates timing benefits around the utilization of certain tax attributes that lead to an effective tax rate in the quarter of approximately 2% to 4%.
Endo International plc Appoints Paul Campanelli to Lead Par Pharmaceutical
Sep 28 15
Endo International plc announced it has completed its previously announced $8.05 billion acquisition of Par Pharmaceutical Holdings Inc. Endo's combined U.S. Generics segment, which includes Par Pharmaceutical and Qualitest, will be named Par Pharmaceutical, an Endo International Company and will be led by Paul Campanelli, former Chief Executive Officer of Par Pharmaceutical, who will also join Endo's Executive Leadership Team.
Endo International plc, Par Pharmaceutical Holdings, Inc. - M&A Call
Sep 28 15
To discuss $8.05 billion acquisition of Par Pharmaceutical Holdings, Inc. and provide financial guidance updates related to the close of the Par acquisition
Depomed to Continue Patent Lawsuit against Endo Pharmaceuticals
Sep 23 15
Depomed said it received a favorable decision from the Patent and Trademark Office on two patents, allowing the company to continue its patent infringement lawsuit against Endo Pharmaceuticals (ENDP) related to pain medicine Opana ER. The Patent and Trademark Office's Patent Trial and Appeal Board confirmed the patentability of all 23 claims of the two patents that were subject to inter parties review proceedings started by Endo.